Showing 571-580 of 19231 results for "".
Emerging Insulin Pump Technology
https://reachmd.com/programs/diabetes-discourse/emerging-insulin-pump-technology/5108/Will insulin pumps become the preferred therapy for patients with type 2 diabetes who are not at goal? New insulin pump technology and patch pumps are offering a whole new level of customization, an ability to improve glucose control and quality of life. Join host Dr. Steven Edelman and his guest, e"I think we're the bridge between the healthcare systems, the pharma systems, and the molecular diagnostic systems," says Matt Newman with Manifold
https://reachmd.com/programs/the-convergence/data-barriers-ai-smarter-faster-care/39923/From streamlining research to informing real-time decisions, AI-powered platforms are beginning to reshape how clinicians and researchers access and apply data in patient care. Learn more as Dr. Brian McDonough speaks with Matt Newman, Senior Vice President of Industry Solutions at Manifold, about hPart 1: A Plant-Based Diet for Preventing and Possibly Reversing Coronary Artery Disease
https://reachmd.com/programs/heart-matters/part-1-a-plant-based-diet-for-preventing-and-possibly-reversing-coronary-artery-disease/6249/Beta blockers, anticoagulants, stenting procedures and bypass surgeries: these are all crucial cornerstones of cardiology that have saved and improved the quality of lives for our patients, yet the underlying causes of coronary artery disease aren't addressed by interventions and medications. Can weGetting to Know GRADE: A Comparative Study of T2D Treatment
https://reachmd.com/programs/diabetes-discourse/getting-to-know-grade-a-comparative-study-of-t2d-treatment/14216/An ancillary study from the landmark GRADE study explores the efficacy of different treatments for type 2 diabetes. What do we need to know about them?AIP Emerges as a Potential Marker for Diabetic Kidney Risk
https://reachmd.com/programs/clinicians-roundtable/aip-emerges-as-a-potential-marker-for-diabetic-kidney-risk/37220/Special Report: What Went Wrong With ACCORD?
https://reachmd.com/programs/clinicians-roundtable/special-report-what-went-wrong-with-accord/3205/What went wrong with the glucose-lowering arm of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Trials? Intensive therapy was expected to reduce cardiovascular events in Type 2 diabetics at high risk of cardiovascular disease. Instead, it appears to have led to an increase in moConcentrating on the MOMPOD Trial for Metformin Plus Insulin
https://reachmd.com/programs/diabetes-discourse/concentrating-on-the-mompod-trial-for-metformin-plus-insulin/17887/Tune in to find out about how metformin plus insulin can help patients with preexisting diabetes or gestational diabetes.VNS Therapy Achieves Cost Neutrality Within 2 Years Across All US Payer Types
https://reachmd.com/programs/practical-neurology/vns-therapy-achieves-cost-neutrality-within-2-years-across-all-us-payer-types/49194/Rethinking MacTel: Cell-based Insights for Vision Preservation
https://reachmd.com/programs/cme/Rethinking-MacTel-Cell-Based-Insights-for-Vision-Preservation/35524/Catch up on the latest information on the management of macular telangiectasia type 2 (MacTel) with a new encapsulated cell therapy, revakinagene taroretcel.What is the Safety of Statins in Patients with Diabetes?
https://reachmd.com/programs/lipid-luminations/what-is-the-safety-of-statins-in-patients-with-diabetes/6967/At the most recent National Lipid Association (NLA) meeting, host Dr. Alan Brown welcomes Kevin Maki, PhD, FNLA, CLS, Chief Science Officer for Midwest Center for Metabolic and Cardiovascular Research and Adjunct Faculty position in Biostatistics and Applied Epidemiology at DePaul University, Chicag